%0 Journal Article
%T Epidemiological and Disease Burden Profiles of Leukemias and Malignant Lymphomas: Overview and Trends in the Republic of Moldova and Worldwide
%A Vasile Musteata
%J International Journal of Clinical Medicine
%P 79-95
%@ 2158-2882
%D 2023
%I Scientific Research Publishing
%R 10.4236/ijcm.2023.142006
%X <strong>Introduction: </strong>Hematological malignancies (HM) are relatively frequent nosological entities within the structure of morbidity by malignant tumors, exhibiting a severe evolution, restrained prognosis and negative socio-economic impact in the advanced stages and phases. <strong>Objective: </strong>The objective of the study was to identify the epidemiological patterns, and to evaluate the epidemiological trends and disease burden issues of HM in the Republic of Moldova and worldwide. <strong>Materials and Methods: </strong>The following research methods were used: epidemiological, descriptive statistics, clinico-analytic. The diagnosis was proved in all cases by histopathological, cytological, cytogenetic, molecular and immunophenotyping examinations. The qualitative type researches were performed and enriched by the narrative synthesis of the data. From the specialized international bibliographic sources and official statistics concerning HM. The narrative review of the reference sources was fulfilled in the form of a synthesis. <strong>Results:</strong> The number of newly diagnosed and followed-up patients with HM at the Institute of Oncology in 2016, 2017, 2018, 2019, 2020 and 2021 amounted respectively to 725, 802, 613, 628, 536 and 528, the incidence (new cases per 100,000 population) being 17.6, 19.5, 14.9, 17.7, 15.1 and 20.3. In 2021 HM constituted 6.2% of all newly-diagnosed cases with malignant tumors in the Republic of Moldova. In the same year Hodgkin lymphoma was diagnosed in 10.04% of cases, non-Hodgkin¨s lymphomas！in 31.63%, multiple myeloma and plasma cells neoplasms！in 7.77%, lymphoid leukemias！in 17.42%, myeloid leukemias！in 12.31%, monocytic leukemias！in 0.95%, and other leukemias！in 16.29%. In 2019 the male rate was 51.5%, and the female rate！48.5%. Within 2 years males were 266 (50.4%), females！262 (49.6%). The age of 50 - 79 years prevailed in both genders (males！65%, females！72.5%). The children constituted 4.0% of the newly diagnosed cases, 4.8% of those under the follow-up at the end of the year 2019 and 6.4% of the newly diagnosed cases in 2021. The disease span from the onset to diagnosis ranged between 1 - 24 months and constituted on average 5.63 months, without a significant difference as compared to 2019 (5.76 months). The incidence of HM in Western countries is 14 - 19 new cases per 100,000 population (4% of all cases with malignant tumors). The incidence of non-Hodgkin¨s lymphomas increased by 45% between 2006 and 2016, from 319,078 to 461,000 cases. Between 2006 and 2016, the incidence of leukemias
%K Hematological Malignancies
%K Epidemiological Patterns
%K Incidence
%K Mortality
%K Disability-Adjusted Life-Years
%K Disease Burden
%K Management
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=123022